ReviewImmunology2026
Immune Checkpoints in Leukaemia as Gatekeepers of Immuno-Modulation.
Review in Immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Immune evasion remains one of the key hallmarks in cancer survival by which tumours avoid immune system response. Mechanism of immune evasion involved modulation of immune related cytokines, modulation of tumour microenvironment and immune checkpoints. Intrinsic workings of these mechanisms lead to a network of 'on' and 'off' switches which could modulate immune activity. Interestingly in leukaemia, a complex network is involved as immune masking occurred concomitantly with leukaemogenesis within the same microenvironment, which makes immune evasion a more elusive hallmark for this disease. Dysregulation of these mechanisms not only facilitates disease persistence and progression but also contributes to resistance against conventional therapies. Therefore, understanding the role of leukaemic immune checkpoints is essential for identifying novel therapeutic targets and improving the efficacy of immunomodulatory treatment strategies. Here, we focus on the leukaemic immune checkpoints as these consist of crucial surface molecules, receptors, ligands, and immunosuppressive cells which interact within the tumour environment to enable leukaemia to elude immune response.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.